Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I/II double-blinded, randomized study

Clinical Cancer Research

Volumn 16, Issue 21, 2010, Pages 5269-5276

  Keizman, Daniel ^a   Zahurak, Marianna ^a   Sinibaldi, Victoria ^a   Carducci, Michael ^a   Denmeade, Samuel ^a   Drake, Charles ^a   Pili, Roberto ^a   Antonarakis, Emmanuel S ^a   Hudock, Susan ^a   Eisenberger, Mario ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Bunting Blaustein Cancer Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; APPENDICITIS; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; TUMOR GROWTH; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; TESTOSTERONE; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 78049477140     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1928     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. [Epub ahead of print].
2. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
3. Moul JW, Bañez LL, Freedland SJ. Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park) 2007;21:1436-45, (Review).
4. Pound C, Partin A, Eisenberger M, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
5. Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005;23:826-31.
6. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
7. Antonarakis ES, Trock BJ, Feng Z, et al. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. J Clin Oncol 2009;27:15s, (suppl; abstr 5008).
8. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-83.
9. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23:6992-8.
10. Figg W, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen independent prostate cancer. Clin Cancer Res 2001;7:1888-93.
11. Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open label phase II study of low dose thalidomide in androgen independent prostate cancer. Br J Cancer 2003;88:822-7.
12. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9.
13. Gaidarova s, Corral LG, Gleizer E, et al. Lenalidomide enhances antitumor effect of γδ T cells against mantle cell lymphoma. Blood 2008;112:906, (Abstract 2616).
14. Gorgun G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A 2009;106:6250-5.
15. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999;163:380-6.
16. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-4.
17. Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009;77:78-86.
18. Dahut WL, Aragon-Ching JB, Woo S, et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009;49:650-60.
19. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-59.
20. Rosenbaum E, Zahurak M, Sinibaldi V, et al. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 2005;11:4437-43.
21. Laufer M, Pound CR, Carducci MA, Eisenberger MA. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000;55:309-15.
22. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
23. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7.
24. Antonarakis ES, Lin J, Keizman D, Carducci MA, Eisenberger MA. The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: combined analysis of three randomized trials. J Clin Oncol 2010;28:15s (suppl;abstr 4549).
25. Maricque BB, Smith HA, Drake C, et al. Detection of autoantibody responses to prostate cancer-associated antigens following treatment of patients with androgen deprivation therapy. American Association for Cancer Research (ACCR) 101st Annual Meeting, Washington (DC); 2010 (Abstract).
26. Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010;148:948-50.